GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ALNY · Jun 30, 2026

ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration

State dimensions

Filing0001178670-26-000062General Corporate
Revenue growth65thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

66.86% · CORE · VALID

Inventory pressure20thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

7.52% · OPTIONAL · VALID

Gross margin5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

76.90% · CORE · VALID

Operating margin90thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

17.93% · CORE · VALID

R&D intensity5thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

32.00% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

6.71% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition

What moved in the state?

Growth Increased
Previous
65.19%
Current
66.86%
Delta
1.66%
Inventory Pressure Increased
Previous
2.23%
Current
7.52%
Delta
5.30%
Margin Decreased
Previous
81.77%
Current
76.90%
Delta
-4.87%
Profitability Increased
Previous
13.51%
Current
17.93%
Delta
4.42%
R And D Intensity Decreased
Previous
35.54%
Current
32.00%
Delta
-3.53%
Sbc Intensity Decreased
Previous
9.38%
Current
6.71%
Delta
-2.67%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Sep 30, 2020
Similarity
94%
Compared
5 dimensions
Coverage
83%
Margin 7.5 · Profitability 10.0 · Sbc Intensity 0.0 · R And D Intensity 5.0 · Inventory Pressure 5.0
Dec 31, 2025
Similarity
88%
Compared
6 dimensions
Coverage
100%
Growth 5.0 · Margin 5.0 · Profitability 0.0 · Sbc Intensity 20.0 · R And D Intensity 5.0 · Inventory Pressure 20.0
Dec 31, 2023
Similarity
85%
Compared
6 dimensions
Coverage
100%
Growth 15.0 · Margin 25.0 · Profitability 5.0 · Sbc Intensity 5.0 · R And D Intensity 0.0 · Inventory Pressure 20.0
Jun 30, 2021
Similarity
85%
Compared
6 dimensions
Coverage
100%
Growth 27.5 · Margin 22.3 · Profitability 10.0 · Sbc Intensity 0.0 · R And D Intensity 5.0 · Inventory Pressure 7.3
Jun 30, 2023
Similarity
78%
Compared
6 dimensions
Coverage
100%
Growth 40.0 · Margin 5.0 · Profitability 5.0 · Sbc Intensity 35.0 · R And D Intensity 0.0 · Inventory Pressure 1.1
Research Graph

Related governed research

Analogous To · ALNY state analogue 2 →Analogous To · ALNY state analogue 5 →Analogous To · ALNY state analogue 1 →Compared To · Pharmaceutical Preparations peers →Analogous To · ALNY state analogue 4 →Analogous To · ALNY state analogue 3 →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY GROWTH_INCREASED →Transitioned To · ALNY INVENTORY_PRESSURE_INCREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.